Evidence map›Paper›PMID 28368378›Full record

ArticleBone marrow transplantation2017

Sinusoidal obstructive syndrome prophylaxis with recombinant human soluble thrombomodulin is feasible in gemtuzumab ozogamicin-treated patients undergoing allogeneic hematopoietic cell transplantation.

S Yamamoto, R Matsuno, Y Sugishita, R Kaneko, N Okamoto, M Koganesawa, S Fujita, K Akiyama, D Toyama, K Isoyama

Abstract read
PubMed Publisher
In one paragraph

Article in Bone marrow transplantation, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

S YamamotoDepartment of Pediatrics, Showa University Fujigaoka Hospital, Yokohama, Japan.
R MatsunoDepartment of Pediatrics, Showa University Fujigaoka Hospital, Yokohama, Japan.
Y SugishitaDepartment of Pediatrics, Showa University Fujigaoka Hospital, Yokohama, Japan.
R KanekoDepartment of Pediatrics, Showa University Fujigaoka Hospital, Yokohama, Japan.
N OkamotoDepartment of Pediatrics, Showa University Fujigaoka Hospital, Yokohama, Japan.
M KoganesawaDepartment of Pediatrics, Showa University Fujigaoka Hospital, Yokohama, Japan.
S FujitaDepartment of Pediatrics, Showa University Fujigaoka Hospital, Yokohama, Japan.
K AkiyamaDepartment of Pediatrics, Showa University Fujigaoka Hospital, Yokohama, Japan.
D ToyamaDepartment of Pediatrics, Showa University Fujigaoka Hospital, Yokohama, Japan.
K IsoyamaDepartment of Pediatrics, Showa University Fujigaoka Hospital, Yokohama, Japan.
Showa University Fujigaoka Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Hematopoietic Stem Cell TransplantationAdolescentAllograftsAminoglycosidesAntibodies, Monoclonal, HumanizedChildChild, PreschoolFemaleGemtuzumabHepatic Veno-Occlusive DiseaseHumansInfantLeukemia, Myeloid, AcuteMaleRecombinant ProteinsThrombomodulinAminoglycosidesAntibodies, Monoclonal, HumanizedGemtuzumabRecombinant ProteinsTHBD protein, humanThrombomodulin

Identifiers

PMID28368378
OpenAlexW2605314633

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.